AVITA Medical/$RCEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AVITA Medical
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
- Ticker
- $RCEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Valencia, United States
- Website
- avitamedical.com
AVITA Medical Metrics
BasicAdvanced
$535M
-
-$1.18
-
-
Price and volume
Market cap
$535M
52-week high
$18.43
52-week low
$3.22
Average daily volume
504K
Financial strength
Current ratio
1.201
Quick ratio
0.905
Long term debt to equity
-1.519
Total debt to equity
-1.519
Interest coverage (TTM)
-3.22%
Profitability
EBITDA (TTM)
-26.224
Gross margin (TTM)
82.36%
Net profit margin (TTM)
-42.65%
Operating margin (TTM)
-33.89%
Effective tax rate (TTM)
-0.19%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-32.45%
Return on equity (TTM)
191.59%
Valuation
Price to revenue (TTM)
6.26
Price to book
-17.26
Price to tangible book (TTM)
-14.64
Price to free cash flow (TTM)
-26.523
Free cash flow yield (TTM)
-3.77%
Free cash flow per share (TTM)
-0.652
Growth
Revenue change (TTM)
16.96%
Earnings per share change (TTM)
-34.94%
3-year revenue growth (CAGR)
23.09%
3-year earnings per share growth (CAGR)
-4.02%
What the Analysts think about AVITA Medical
Analyst ratings (Buy, Hold, Sell) for AVITA Medical stock.
Analyst projections of the future price of AVITA Medical stock.
Bulls say / Bears say
RECELL momentum is accelerating: US revenue rose about 20% sequentially in Q3, helping lift total revenue 53% year on year. Management raised 2026 revenue guidance to $92–94 million and expects cash-flow breakeven in Q4. (AVITA Medical)
New national Medicare physician payment values and simpler billing codes for RECELL procedures take effect in January 2027. This could make physician payment more predictable, although Medicare coverage rules still apply. (AVITA Medical)
The wider wound-care portfolio offers room to grow beyond RECELL: Cohealyx revenue rose about 21% sequentially in Q3, while a PermeaDerm study found comparable outcomes to allograft with lower product costs and much less preparation time. (AVITA Medical)
Management said Q3 may have benefited from the summer peak in burn admissions, yet its Q4 guidance calls for $24.9–26.9 million in revenue. Seasonal demand could make that target harder to deliver. (The Motley Fool)
The business remains loss-making: AVITA reported a $24.5 million net loss for the first nine months of 2026. Its $60 million of credit-facility borrowings also leave substantial debt and interest costs despite improved cash use. (SEC)
RECELL still supplies most sales: it generated $23.1 million of Q3 commercial revenue out of $26.0 million. Cohealyx and PermeaDerm remain small contributors, and PermeaDerm revenue was flat sequentially, leaving diversification and adoption risks. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
AVITA Medical Financial Performance
Revenues and expenses
AVITA Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
AVITA Medical News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.